USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/19710
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrib, Andrei
dc.contributor.authorAbraș, Marcel
dc.contributor.authorMazur-Nicorici, Lucia
dc.date.accessioned2022-01-27T08:36:53Z
dc.date.available2022-01-27T08:36:53Z
dc.date.issued2012
dc.identifier.citationGRIB, Andrei, ABRAŞ, Marcel, MAZUR-NICORICI, Lucia. Dyslipidemia and hyperglycemia in hypertensive patients with metabolic syndrome. In: MedEspera: the 4th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2012, pp. 109-110.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/19710
dc.description.abstractIntroduction: Metabolic syndrome (MS) is a combination of interrelated risk factors, which include: dyslipidemia (DLP), hyperglycemia, high blood pressure, and abdominal obesity. This coexistence of metabolic disorders promotes atherosclerotic cardiovascular disease, being also a causative factor for type 2 difabetes mellitus (DM). Hypertension is one of the most common manifestations of MS, which has a high prevalence worldwide (25-35% in adults and 60-70% in people over 70 years) due to the global epidemic of DM and obesity. Another association of hypertension and MS is DLP, induced by the action of insulin on lipid metabolism, which increases very low density lipoprotein synthesis in the liver. Methods: It was a retrospective study of patients from the Institute of Cardiology, the key criterion being grade I-II hypertension. Diagnosis of MS was established according to criteria proposed by NCEP/ ATP III in 2005. MS was considered in patients having at least 3 of 5 criteria. DM was established according to American Diabetes Association definition in 2003. Results: There were 168 hypertensive patients included of which we selected 114 patients with grade I-II hypertension divided subsequently into four groups: with MS and DM (n=32); with MS, but no DM (n=29); no MS and no DM (n=37); no MS, but with DM (n=16). Following evaluation in these groups included determination of lipid and glucose metabolism features. Patients with MS only had significantly higher TG levels than patients with DM only (2.23±0,04 vs. 1.30±0,06 mmol/1, respectively). Similarly, values of TC and LDL-C were highest in patients with MS only (5.80±0.04 and 4.71±0.03 mmol/1, respectively). Serum levels of HDL-C had shown inverse correlations compared with TG. Calculating the atherogenic coefficient revealed that TC/HDL-C ratio is significantly higher in MS groups compared to non-MS groups, independently of the presence of DM. Evaluation of glucose metabolism in the study group revealed that 45 (39.5%) patients were diagnosed with type 2 diabetes and 69 (60.51%) patients were nondiabetic, of which 38 (33.3%) patients with impaired glucose homeostasis (IGH) and 31 (27.2%) patients with normal glucose regulation (NGR). Group assessment found that IGH meets in higher proportion among nondiabetic patients with MS (84.4%), than among nondiabetic patients without MS (29.7%). Conclusions: Lipid metabolism disorders is more common in the group of hypertensive patients with MS, and were not altered by the presence of DM. DLP was mainly manifested by a significant reduction in HDL-C, high levels of TG, TC and LDL-C and increased TC/HDL-C ratio, which implies a more enhanced atherogenic activity in groups of patients with MS. Glucose metabolism disorders are common in 72.8% of hypertensive patients and only 27.2% of them have normal glucose regulation. Comparison of nondiabetic groups revealed that IGH meets in higher proportion among nondiabetic patients with MS, than among nondiabetic patients without MS. Thus, hyperglycemia is highly associated with hypertension, particularly in patients with MS.en_US
dc.language.isoenen_US
dc.publisherState Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association, Scientific Association of Students and Young Doctorsen_US
dc.relation.ispartofMedEspera: The 4th International Medical Congress for Students and Young Doctors, May 17-19, 2012, Chisinau, Republic of Moldovaen_US
dc.subjecthypertensionen_US
dc.subjectmetabolic syndromeen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.subjectDLPen_US
dc.subjecthyperglycemiaen_US
dc.titleDyslipidemia and hyperglycemia in hypertensive patients with metabolic syndromeen_US
dc.typeOtheren_US
Appears in Collections:MedEspera 2012

Files in This Item:
File Description SizeFormat 
DYSLIPIDEMIA_AND_HYPERGLYCEMIA_IN_HYPERTENSIVE_PATIENTS_WITH_METABOLIC_SYNDROME.pdf112.37 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback